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Abstract 
Through the reductive amination of N-[(tert-butoxy)carbonyl]-2,5-dideoxy-2,5-imino-3,4-O-
isopropylidene-L-ribose with tetramethylenediamine, hexamethylenediamine, 2,7-
diaminofluorene, 4,4'-diaminodiphenylmethane and 1,4-(diaminomethyl)benzene, five 
tetramines containing two (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol moieties have been 
prepared and assayed for their inhibitory activities toward 24 glycosidases. Tetramines 
containing the tetramethylene or benzene-1,4-dimethylene linkers are more potent α-
mannosidase inhibitors than simple (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diols. Triamines 
such as (2S,3R,4S)-bis(3,4-dihydroxy-pyrrolidin-2-ethyl)amine were also prepared and shown to 
be better α-mannosidase inhibitors than (2S,3R,4S)-2-(2-aminoethyl)pyrrolidin-3,4-diol. 
 







Cell sociology involves a language based on molecular recognition between cell-surface 
carbohydrates and proteins.1 The biosynthesis of the surface oligosaccharides uses 
glycosyltransferases and glycosidases as catalysts. Inhibitors of these enzymes2 are important 
molecular tools for glycobiology, and can be used to modulate cellular functions. They are also 
potential drugs in new therapeutic strategies.3 Among the most potent glycosidase inhibitors are 
polyhydroxypiperidines (1,5-dideoxy-1,5-iminoalditols) that are mimics of the glycosyl cation 
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intermediates liberated during enzyme-catalyzed hydrolytic processes.4,5 Derivatives of 3,4-
dihydroxypyrrolidines (1,4-dideoxy-1,4-iminoalditols) also emerge as an important class of 
glycosidase4a,5,6 and glycosyltransferase7 inhibitors. Simple meso-3,4-dihydroxypyrrolidine 1 is a 
non-selective, weak inhibitor of several glycosidases (Figure 1).8 We have found that derivatives 
2b with (2R)-aminomethyl side chains can be highly selective and competitive inhibitors of α-











1 2a R = H





Figure 1. Inhibitors of glycosidases and glycosyltransferases. 
 
Clinical trials have shown that swainsonine 3, a natural α-mannosidase inhibitor that contains 
a 4-amino-4-deoxy-mannofuranoside moiety,9,10 reduces solid tumors and hematological 
malignancies.11 Analogues of 3 have also shown interesting properties.12 Mannosidase inhibitors 
mediate increased secretion of mutant α1-antitrypsin Z. They are thus leads in the development 
of drugs for the chemoprophylaxis of liver injury and emphysema in patients with α1-antitrypsin 
Z deficiency.13 Mannostatin A and B isolated from the soil microorganism Streptoverticillum 
verticillus14 and a synthetic analogue15 are probably the most potent inhibitors of α-
mannosidases reported so far.16 Often α-mannosidase inhibitors that are monosaccharide 
mimics4a,17 also inhibit other types of glycosidases,18 in particular α-L-fucosidases.4a,19 To 
become a drug, a good inhibitor must satisfy a number of conditions apart from its low toxicity 
and enzyme specificity.20 We have envisioned that polyamines containing two (2R,3R,4S)-2-
(aminomethyl)-3,4-dihydroxypyrrolidine fragments could be alternative α-mannosidase 
inhibitors with improved pharmacological properties. We report here the synthesis of five 
tetramines 4 (Figure 2). We have also prepared triamine 5 that contains two (2S,3R,4S)-2-(1-
aminoeth-2-yl)-3,4-dihydroxypyrrolidine moieties, as well as its enantiomer ent-5. These new 
compounds have been assayed for their inhibitory activity toward 24 commercially available 
glycosidases, and in particular toward α-mannosidase from jack bean, an enzyme known to be a 
useful model for mammalian α-mannosidases such as Golgi α-mannosidase II.21 Whereas 
triamine ent-5 does not inhibit any of the enzyme tested (except for a poor 38% inhibition of β-
glucosidase from almond at 1 mM concentration), its enantiomer 5 is a moderate inhibitor of α-
mannosidase from jack bean (Ki = 74 µM) and from almond (Ki = 92 µM). Among the five 
tetramines 4, best inhibitory activities toward these enzymes were found with 4a and 4e. But 
contrary to inhibitors of type 2b, these polyamines are less enzyme selective. 
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Figure 2. Tri- and tetramines containing two 2,3-dihydroxypyrrolidine moieties. 
 
 
Results and Discussion  
 
Synthesis of the polyamines 
Tetramines 4 were all prepared from aldehyde 68 by reaction with the corresponding diamine 
H2N-A-NH2 (1.8 equivalent) in the presence of NaBH(OAc)322 for in situ reduction of the 





















4(a-e), 50 to 90% yield  
 
Scheme 1. Synthesis of tetramines 4. 
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The so-formed semi-protected tetramines were treated with aqueous CF3COOH, at room 
temperature, to cleave the Boc and acetonide moieties. Overall yields based on 6 ranged from 50 
to 90%. 
Triamines 5 and ent-5 were derived from aldehydes 8 and ent-8, themselves derived from L- 
and D-arabinose, respectively23,24 (Scheme 2). Treatment of a 1:1.1 mixture of 8 and 
benzylamine with NaBH(OAc)3 in 1,2-dichloroethane resulted in the formation of 9 and 10 with 
46% and 18% yield, respectively. Using a half equivalent of benzylamine, 10 was obtained in 
55% yield. Hydrogenolysis of the benzyl group (10% Pd / charcoal, THF/MeOH) gave 11 in 
98% yield. Deprotection under acidic conditions provided 5 in almost quantitative yield. The 
same reactions were applied to ent-8 providing ent-(9–13). Compound ent-8 was obtained from 
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Scheme 2. Preparation of triamines 5 and ent-5.  
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Glycosidase inhibitory activities 
Appropriate p-nitrophenyl pyranosides were used as substrates and commercially available 
glycosidases (see below and Table) were used as catalysts of the buffered hydrolysis under 
optimal pH.25 At 1 mM concentration and under optimal pH conditions tetramines 4 and 
triamines 5 and ent-5 did not inhibit the following enzymes: α-L-fucosidase from bovine 
epididymis, α-D-galactosidases from coffee bean, Aspergillus niger and E. coli, β-galactosidase 
from orizae, β-D-mannosidase from Helix pomatia, β-N-acetylgalactosamidase from jack bean, 
bovine epididymis A and B. The inhibitory activities toward other glycosidases are reported in 
Table 1. 
We have found that (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol 2a is a weak inhibitor of 
α-mannosidase from jack bean and from almond. This diamine also moderately inhibits β-
galactosidases, α-glucosidases and β-glucosidases. Derivatives 2b are much better and more 
selective α-mannosidase inhibitors.8 Thus, we expected that compounds 4 and 5 would also 
show improved inhibitory activities toward α-mannosidases. This is indeed the case for 4a with 
the tetramethylene linker, and for 4e with the p-benzenedimethylene spacer. Both are 
competitive inhibitors. The bad surprise is that these tetramines also inhibit other glycosidases, 
moderately though, except for 4a which is a good, non-competitive inhibitor of β-glucosidase 
from almond. This result suggests that 4a "sticks" to this enzyme and inhibits it for allosteric 
reasons, a mechanism different from that making 4a a competitive inhibitor of α-mannosidases. 
Tetramine 4b with the hexamethylene linker and analogues 4c and 4d with diphenylmethane 
linkers are poor inhibitors in terms of both potency and selectivity. They are even worse than 
simple diamine 2a. As (2S,3R,4S)-2-(2-aminoethyl)pyrrolidine-3,4-diol 13 is a weak inhibitor of 
α-mannosidase, although the side chain is in a β-configuration rather than α, we envisioned that 
triamine 5 might have improved inhibitory activity. Interestingly, we find 5 to be a more potent 
α-mannosidase inhibitor than 13. Unfortunately, it is not a more selective inhibitor than 13 
because it inhibits moderately a few α-glucosidases, β-glucosidases and α-N-acetyl-
galactosamidase from chicken liver (Table 1). As expected, triamine ent-5, which does not share 
the configuration of any of the hexoses liberated during the hydrolytical process catalyzed by the 





The conjugation of two (2R,3R,4S)-2-(2-aminomethyl)pyrrolidine-3,4-diols by their primary 
amines to alkane or arene linkers can generate potent α-mannosidase inhibitors. This work opens 
a new road in the search for new glycosidase inhibitors. Analogues of tetramines 4a and 4e that 
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Table 1. Inhibitory activities of diamines 2a, 2b, triamines 5 and ent-5 and tetramines 4a-4e. 
Percentage of inhibition at 1mM concentration, IC50 (in parenthesis) and Ki in µM, optimal pH, 
35°C25,26 







































































































































































































































































General Procedures. All commercially available reagents (Fluka, Aldrich) were used without 
further purification. Solvents were dried by standard methods. Light petroleum ether used refers 
to the fraction boiling at 40–60 °C. Solutions after reactions and extractions were evaporated in a 
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rotatory evaporator under reduced pressure. Liquid/solid flash chromatography (FC): columns of 
silica gel (Merck No.9385 silica gel 60, 240–400 mesh). TLC for reaction monitoring: Merck 
silica gel 60F254 plates; detection by UV light, Pancaldi reagent [(NH4)6MoO4, Ce(SO4)2, H2SO4, 
H2O] or KMnO4. IR spectra: Perkin-Elmer-1420 spectrometer. Optical rotations were determined 
at room temperature on a Jasco DIP-370 polarimeter. [α]D values are given in units of 10–1 deg cm2 g–1. 
1H NMR spectra: Bruker-ARX-400 spectrometer (400 MHz), Bruker AMX-300 spectrometer 
(300 MHz); δ(H) in ppm relative to the solvent’s residual 1H signal [CHCl3, δ(H) 7.27; CH3OD, 
δ(H) 3.31; D2O, δ(H) 4.79; DMSO-d6, δ(H) 2.54] as internal reference; all 1H assigments were 
confirmed by 2D-COSY-45 and 2D-NOESY spectra. 13C NMR spectra: same instrument as 
above (100.6 MHz and 75.4 MHz); δ(C) in ppm relative to the solvent’s C-signal [CDCl3, δ(C) 
77.0; CD3OD, δ(C) 49.8; DMSO-d6 δ(C) 39.7] as internal reference; all 13C assigments were 
confirmed by 2D-HMQC; coupling constants J in Hz. MS: Nermag R 10-10C, chemical 
ionization (NH3) mode m/z (amu) [% relative to base peak (100%)]. High resolution mass 
spectrometry: Micromass AutoSpecQ, resolution of 10000 (5% valley definition). Elemental 
analyses: Ilse Beetz, D-96301 Kronach, Germany. 
 
Glycosidase inhibitions. A known protocol was applied.25,26 We verified that the delay of 
inhibitor/enzyme incubation did not affect the inhibition measurements. Under standard 
conditions, optimal inhibitory activities were measured after five minutes of incubation. 
 
Reductive amination. General procedure A. To a solution of N-[(t-butoxy)carbonyl]-2,5-
dideoxy-2,5-imino-3,4-O-isopropylidene-L-ribose (200 mg, 0.737 mmol) in anhydrous 1,2-di-
chloroethane (7 mL) were added the diamine (0.6 eq, 0.442 mmol) and NaBH(OAc)3 (1.8 eq, 
281 mg, 1.327 mmol). The solution was stirred at 50 °C for 12 h and then poured into a sat. aq 
solution of NaHCO3 (20 mL). The mixture was extracted with EtOAc (3 x 20 mL). The 
combined organic extracts were dried (MgSO4) and concentrated under reduced pressure. The 
residue was directly used in the deprotection step.  
 
Reductive amination. General procedure B. To a solution of N-[(t-butoxy)carbonyl]-2,3,6-
trideoxy-3,6-imino-4,5-O-isopropylidene-L- (or D-) arabino-hexose (1 mmol) in anhydrous 1,2-
dihloroethane (3 mL) were added benzylamine (118 mg, 1.1 mmol) and NaBH(OAc)3 (276 mg, 
1.3 mmol). The solution was stirred at r.t. for 3 h and then poured into a sat. aq solution of 
NaHCO3 (20 mL). The mixture was extracted with EtOAc (3 x 20 mL) and the combined 
organic extracts were dried (MgSO4). After solvent evaporation under reduced pressure the 
residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH 60:1 to 5:1). 
 
Deprotection. General procedure C. A solution of bis (pyrrolidine) derivatives in CF3COOH / 
H2O (4:1; 5–10%) was stirred at 20 °C for 2 h. After solvent evaporation in vacuo, the residue 
was purified by flash chromatography on silica gel (MeCN/aq NH3). 
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Deprotection. General procedure D. A solution of the protected pyrrolidine derivative 
(0.1 mmol) in CF3COOH H2O (4:1; 3 mL) was stirred at 20 °C for 2 h. The mixture was passed 
through a Dowex 50WX8 (100–200 mesh) column and eluted, successively with MeOH 
(30 mL), H2O (30 mL) and NH4OH (10%, 50 mL). The fractions containing the unprotected 
product were concentrated to yield the corresponding pyrrolidine derivative. 
(2R,3R,4S)-2-[[4-[[[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl]amino]butyl]amino-
methyl]pyrrolidine-3,4-diol (4a). Procedure A was applied to 1,4-diaminobutane (45 µL, 
0.442 mmol) to afford crude 7a (180 mg). Deprotection according to procedure C gave 4a 
(127 mg, 90%, 2 steps) as a pale orange oil. Rf = 0.15 (MeCN / NH4OH 1:1). [α] 589
25 = –106, 
[α] 577
25  = –262, [α] 546
25  = –409, [α] 435
25  = –690, [α] 405
25  = –1114 (c = 0.25, H2O). IR (film): v~  3500–
2900, 1440, 1200, 1140, 840, 800, 710, 695 cm-1. UV (MeCN): λmax (ε) 195 (1360). 1H NMR 
(D2O): δ 4.11 (m, 2H, H-4, H-4IV), 3.94 (dd, 2H, 3J = 10.7, 3J = 3.9 Hz, H-3, H-3IV), 3.75 (ddd, 
2H, 3J = 10.7, 3J = 5.1, 3J = 3.3 Hz, H-2, H-2IV), 3.23 (dd, 2H, 2J = 9.3, 3J = 2.1, H-5, H-5IV), 
3.13 (dd, 2H, 2J = 12.6, 3J = 5.1, H-1', H-1'''), 3.09−3.01 (m, 2H, H-5, H-5IV), 2.81 (dd, 2H, 2J = 
12.6, 3J = 3.3, H-1', H-1'''), 2.72–2.64 (m, 4H, H-1'', H-4''), 1.71−1.56 (m, 4H, H-2'', H-3''). 13C 
NMR (D2O): δ 76.9 (d, C-3, C-3IV), 73.5 (d, C-4, C-4IV), 60.7 (d, C-2, C-2IV), 53.9 (t, C-5, C-
5IV), 52.6 (t, C-1, C-1'''), 50.4 (t, C-1'', C-4''), 26.3 (t, C-2'', C-3''). CI-MS: m/z 319 (100, M + 
H+), 293 (74), 204 (33), 133 (35), 102 (36), 84 (55). Anal. calcd for C14H30N4O4 (318.42): C, 
52.81; H, 9.50. Found: C, 52.79; H, 9.32.  
(2R,3R,4S)-2-[[6-[[[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl]aminohexyl]amino-
methyl]pyrrolidine-3,4-diol (4b). Procedure A was applied to 1,6-diaminohexane (51 mg, 
0.442 mmol) to afford crude 7b (155 mg). Deprotection according to procedure C gave 4b 
(86 mg, 56% yield, 2 steps) as a colorless oil. Rf = 0.1 (MeCN, NH4OH 1/1). [α] 589
25 = −54 (c = 
0.5, H2O). IR (film): v~  3500−2900, 1450, 1195, 1150, 840, 800, 705, 700 cm-1. UV (MeCN): 
λmax (ε) 197 (1450). 1H NMR (D2O): δ 4.18 (m, 2H, H-4, H-4IV), 3.95 (dd, 2H, 3J = 5.4, 3J = 2.7 
Hz, H-3, H-3IV), 3.75 (m, 2H, H-2, H-2IV), 3.29 (m, 2H, H-5, H-5IV), 3.15 2H, (2H, dd, 2J = 13.2, 
3J = 4.8, H-1', H-1'''), 3.09 (m, 2H, H-5, H-5IV), 2.94 (dd, 2H, 2J = 13.2, 3J = 3.1, H-1', H-1'''), 
2.73 (m, 4H, H-1'', H-6''), 1.65-1.54 (m, 4H, H-2'', H-5''), 1.38 (m, 4H, H-3'', H-4''). 13C NMR 
(D2O): δ 77.0 (d, C-3, C-3IV), 71.7 (d, C-4, C-4IV), 60.7 (d, C-2, C-2IV), 54.2 (t, C-5, C-5IV), 52.6 
(t, C-1, C-1'''), 50.9 (t, C-1'', C-6''), 29.7 (t, C-2'', C-5''), 26.3 (t, C-3'', C-4''). CI-MS: m/z 347 (28, 
M + H+), 274 (9), 232 (12), 117 (100), 98 (85), 86 (63). Anal. calcd for C16H34N4O4 (346.47): C, 
55.47; H, 9.89; N, 16.17. Found: C, 55.18; H, 9.70; N, 16.01. 
 (2R,3R,4S)-2-[4-[4-[[[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl]amino]benzyl]phenyl-
aminomethyl]pyrrolidine-3,4-diol (4c). Procedure A was applied to 4,4'-diaminodiphenyl-
methane (88 mg, 0.442 mmol) to afford crude 7c (150 mg). Deprotection according to procedure 
C gave 4c (113 mg, 60% yield, 2 steps) as a pale yellow oil. Rf = 0.10 (MeCN/NH4OH 4:1). 
[α] 589
25 = +27, [α] 577
25  = +34, [α] 546
25  = +41 (c = 0.9, MeOH). IR (film): v~  3400−3200, 2950, 1675, 
1515, 1450, 1205, 1140, 1025, 725 cm-1. UV (MeCN): λmax (ε) 260 (7250), 207 (13980). 1H 
NMR (MeOD): δ 6.94, 6.68 (2d, 8H, 3J = 8.5 Hz, H-2'', H-6'', H-3VI, H-5VI), 4.29 (m, 2H, H-4, 
H-4VI), 4.08 (dd, 2H, 3J = 8.6, 3J = 4.0 Hz, H-3, H-3VI), 3.80 (bs, 2H, 2H-1'''), 3.76 (ddd, 2H, 3J = 
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9.1, 3J = 8.6, 3J = 3.7 Hz, H-2, H-2VI), 3.60 (dd, 2H, 2J = 14.4, 3J = 3.7 Hz, H-1', H-1V), 3.48 (dd, 
2H, 2J = 14.4, 3J = 4.0 Hz, H-5, H-5VI), 3.45 (dd, 2H, 2J = 14.4, 3J = 3.7 Hz, H-1', H-1V), 3.27 
(dd, 2H, 2J = 14.4, 3J = 1.9 Hz, H-5, H-5VI). 13C NMR (MeOD): δ 133.3 (s, C-1'', C-4IV), 133.2 
(d, C-2'', C-6'', C-3IV, C-5IV), 122.3 (s, C-4'', C-1IV), 116.9 (d, C-3'', C-5'', C-2IV, C-6IV), 77.3 (d, 
C-3, C-3VI), 73.5 (d, C-4, C-4VI), 64.0 (d, C-2, C-2VI), 53.3 (t, C-5, C-5VI), 47.1 (t, C-1', C-1V), 
43.8 (t, C-1'''). Anal. calcd for C23H30N4O4 (426.51): C, 64.77; H, 7.09; N, 13.14. Found: C, 
64.34; H, 7.28; N, 12.99. 
(2R,3R,4S)-2-[[7-[[[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl]amino]-9H-fluoren-2-
yl]aminomethyl]pyrrolidine-3,4-diol (4d). Procedure A was applied with 2,7-diaminofluorene 
(87 mg, 0.442 mmol) to afford crude 7d (153 mg). Deprotection according to procedure C gave 
4d (94 mg, 50% yield, 2 steps) as a pale yellow oil. Rf = 0.09 (MeCN/NH4OH 2/1). [α] 589
25 = −62, 
[α] 577
25  = −74, [α] 546
25  = −103, [α] 435
25  = −107, [α] 405
25  = −130 (c = 1, MeOH). IR (film): v~  3400− 
3200, 2960, 1675, 1520, 1455, 1210, 1135, 125, 880, 765 cm-1. UV (MeCN): λmax (ε) 308 
(5820), 215 (5680), 203 (6200). 1H NMR (MeOD): δ 7.43 (d, 2H, 3J = 8.1 Hz, H-3'', H-6''), 6.92 
(bs, 2H, H-1'', H-8''), 6.71 (d, 2H, 3J = 8.1 Hz, H-4'', H-5''), 4.32 (m, 2H, H-4, H-4IV), 4.13 (dd, 
2H, 3J = 8.5, 3J = 4.0 Hz, H-3, H-3IV), 3.82 (ddd,2H, 3J = 8.5, 3J = 8.4, 3J = 3.8 Hz, H-2, H-2IV), 
3.73 (bs, 2H, H-9''), 3.67 (dm, 2H, 2J = 13.3 Hz, H-5, H-5IV), 3.52 (m, 2H, H-5, H-5IV), 3.51 (dd, 
2H, 2J = 12.6, 3J = 4.0 Hz, H-1', H-1'''), 3.30 (dd, 2H, 2J = 12.6, 3J = 1.8 Hz, H-1', H-1'''). 13C 
NMR (MeOD): δ 148.2, 146.2 (2s, C-4a'', C-4b'', C-8a'', C-9a''), 121.0 (s, C-2'', C-7''), 120.5 (d, 
C-3'', C-6''), 114.2 (d, C-4'', C-5''), 111.9 (d, C-1'', C-8''), 75.7 (d, C-3, C-3IV), 71.9 (d, C-4, C-
4IV), 62.5 (d, C-2, C-2IV), 51.7 (t, C-1', C-1'''), 45.7 (d, C-5, C-5IV), 42.1 (t, C-9''). CI-MS: m/z 
427 (21, M + H+), 370 (14), 311 (50), 197 (28), 98 (100), 80 (57). Anal. calcd for C23H30N4O4 
(426.51): C, 64.77; H, 7.09. Found: C, 64.88; H, 7.23.  
(2R,3R,4S)-2-[[4-[[[(2R,3R,4S)-3,4-Dihydroxypyrrolidin-2-yl]methyl]aminomethyl]benzyl]-
aminomethyl]pyrrolidine-3,4-diol (4e). Procedure A was applied with 1,4-(diamino-
methyl)benzene (60 mg, 0.442 mmmol) to afford crude 7e (157 mg). Deprotection according to 
procedure C gave 4e (89 mg, 55% yield, 2 steps) as a colorless oil. Rf = 0.14 (MeCN/NH4OH 
1:1). [α] 589
25 = + 57, [α] 577
25  = + 77, [α] 546
25  = + 83, [α] 435
25  = + 93, [α] 405
25  = + 110 (c = 0.65, H2O). IR 
(film): v~  3500−3000, 1675, 1425, 1200, 1130, 835, 800, 740, 700 cm-1. UV (MeCN): λmax (ε) 
197 (5600). 1H NMR (D2O): δ 7.50 (bs, 4H, Harom), 4.26 (m, 2H, H-4, H-4VI), 3.94 (s, 4H, 2H-1'', 
2H-1IV), 3.87 (dd, 2H, 3J = 7.6, 5.0 Hz, H-3, H-3VI), 3.30−3.25 (m, 4H, H-2, H-2VI, H-5, H-5VI), 
2.99-2.94 (m, 4H, H-1', H-1V, H-5, H-5VI), 2.79 (dd, 2H, 2J = 12.5, 3J = 8.6 Hz, H-1', H-1V). 13C 
NMR (D2O): δ 137.4 (s, C-1''', C-4'''), 129.2 (d, C-2''', C-3''', C-5''', C-6'''), 75.2 (d, C-3, C-3VI), 
70.9 (d, C-4, C-4VI), 59.9 (t, C-1'', C-1IV), 52.1 (t, C-5, C-5VI), 50.6 (d, C-2, C-2VI), 50.0 (t, C-1', 
C-1V). CI-MS : m/z 368 (24, M+), 252 (7), 133 (100), 117 (59). Anal. calcd for C18H32N4O4 
(368.48): C 58.67; H 8.75; N 15.21. Found: C 58.42, H 8.60, N 15.12. 
N-(tert-Butoxycarbonyl)-(2S,3R,4S)-2-[2-(benzylamino)ethyl]-3,4-O-isopropylidenepyrrol-
idine-3,4-diol (9) and N,N-bis[N-(tert-butoxycarbonyl)-[(2S,3R,4S)-3,4-O-isopropylidenoxy-
pyrrolidinyl]ethyl]benzylamine (10). Procedure B was applied to carbaldehyde 823 (298 mg, 
1.05 mmol) affording 9 (178.8 mg, 46%) as oil and 10 (123.4 mg, 18%) as white solid.  
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9. [α] 589
25 = +46 (c = 0.94, CH2Cl2). IR (KBr): v~  3335, 1705, 1470, 1405, 1085, 735, 695 cm-1. 1H 
NMR (DMSO-d6, 90 ºC): δ 7.36−7.27 (m, 5H, Harom), 4.71−4.64 (m, 2H, H-3, H-4), 3.83 (m, 1H, 
H-2), 3.75 (d, 1H, 2J = 13.6, CH2Ph), 3.70 (d, 1H, 2J = 13.6, CH2Ph), 3.67 (dd, 1H, 3J = 7.0, 2J = 
12.2, H-5), 3.13 (dd, 1H, 3J = 3.3, H-5), 3.00 (bs, 1H, NH), 2.65 (ddd, 1H, 2J = 11.6, H-2’), 2.59 
(ddd, 1H, H-2’), 1.93 (dq, 1H, 3J = 6.5, 2J = 13.3, H-1’), 1.81 (dq, 1H, 3J = 6.1, H-1’), 1.39 (s, 
9H, C(CH3)3), 1.42 and 1.26 (2s, 6H, C(CH3)2). 13C NMR (DMSO-d6 90ºC): δ 153.4 (s, CO), 
139.7 (s, Carom), 127.5, 127.4, 125.9 (3d, Carom), 111.2 (s, C(CH3)2), 79.3, 76.7 (2d, C-3, C-4), 
78.4 (s, CMe3), 57.3 (d, C-2), 52.4 (t, CH2Ph), 50.0 (t, C-5), 45.3 (t, C-2’), 28.8 (t, C-1’), 27.6 (q, 
C(CH3)3), 26.0, 24.6 (2q, C(CH3)2). CI-MS: m/z 377 (100, [M+H]+). CI-HRMS: m/z 377.2439 
(calcd for C21H32N2O4+H: 223.1446). 
10. [α] 589
25 = +81 (c = 0.98, CH2Cl2). IR (KBr): v~  1700, 1400, 1165, 1100, 870, 735 cm-1. 1H 
NMR (CDCl3): δ 7.36−7.16 (m, 5H, Harom), 4.49 (m, 2H, H-4), 4.53 (dd, 2H, 3J = 6.1, 3J = 6.1, 
H-3), 3.83 (ddd, 2H, 3J = 9.3, 3J = 6.1, 3J = 5.4, H-2), 3.80 (d, 1H, 2J = 12.9, CH2Ph), 3.77 (dd, 2J 
= 12.1, 3J = 7.1, H-5), 3.60 (d, 1H, 2J = 12.9, CH2Ph), 3.24 (dd, 2H, 2J = 12.1, 3J = 4.7, H-5), 
2.63 (dt, 2J = 12.8, 3J = 7.8, H-2'), 2.50 (ddd, 2H, 2J = 12.8, 3J = 8.4, 3J = 4.4, H-2'), 1.42 (s, 18H, 
tBu), 1.47, 1.27 (2s, 6H, C(CH3)2). 13C NMR (CDCl3): δ 154.2 (s, CO), 140.2 (s, Carom), 129.0, 
127.8, 126.3 (3d, Carom), 112.2 (s, C(CH3)2), 79.3 (d, C-3), 77.3 (s, CMe3), 77.3 (d, C-4), 58.2 
(d, C-2), 58.0 (t, CH2Ph), 50.7, 50.6 (2t, C-5, C-2'), 28.3 (q, C(CH3)3), 26.5 (t, C-1'), 26.7, 25.0 
(2q, C(CH3)2). CI-MS: m/z 646 (100, M + H+). CI-HRMS: m/z 646.4069 (calcd for 
C35H55N3O8+H: 646.4067). 
N-(tert-Butoxycarbonyl)-(2S,3R,4S)-2-aminoethyl-3,4-O-isopropylidenepyrrolidine-3,4-diol 
(11). A solution of 9 (131.6 mg, 0.35 mmol) in abs. EtOH (7 mL) was hydrogenated with 
catalyst Pd/C (10%, 55 mg) at 1 atm for 2 h. The mixture was filtered through Celite, and the 
filtrate was evaporated to give 11 (101 mg, 100%) as a syrup. [α] 589
25 = +48 (c = 0.6, CH2Cl2). IR 
(KBr): v~  1695, 1400, 1090, 800, 735 cm-1. 1H NMR (DMSO-d6, 90 ºC): δ 4.77−4.70 (m, 2H, H-
3, H-4), 3.84 (m, 1H, H-2), 3.68 (dd, 1H, 2J = 12.0, 3J= 7.2, H-5), 3.14 (dd, 1H, 3J = 3.4, H-5), 
2.66-2.62 (m, 3H, H-2’, H-2’, NH), 1.87-1.71 (m, 3H, H-1’, H-1’, NH), 1.43 and 1.29 (2s, 6H 
C(CH3)2), 1.41 (s, 9H, C(CH3)3). 13C NMR (DMSO-d6, 90 ºC): δ 153.4 (s, CO), 111.2 (s, 
C(CH3)2), 79.2, 76.8 (2d, C-4, C-3), 78.3 (s, C(CH3)3), 56.9 (d, C-2), 49.9 (t, C-5), 38.2 (t, C-2’), 
32.4 (t, C-1’), 27.6 (q, C(CH3)3), 25.9 and 24.6 (2q, C(CH3)2). CI-MS: m/z 287 (85, [M+H]+). CI-
HRMS: m/z 287.1971 (calcd for C21H33N2O4+H: 287.1980). 
N,N-Bis-[N-(tert-butoxycarbonyl)-[(2S,3R,4S)-3,4-O-isopropylidenoxy-pyrrolidinyl]ethyl]-
amine (12). A solution of 10 (115 mg, 0.18 mmol) in THF/MeOH (1:1, 4 mL) was hydrogenated 
with Pd/C (10%, 28 mg) at 1 atm for 2.5 h. The mixture was filtered through a pad of Celite and 
evaporated in vacuo to afford 11 as a white solid (97 mg, 98% yield). [α] 589
25 = +57 (c = 0.77, 
CH2Cl2). IR (KBr): v~  3335, 1705, 1470, 1405, 1085, 865, 735 cm-1. 1H NMR (DMSO-d6): δ 
4.77–4.70 (m, 4H, H-3, H-4), 3.84 (m, 2H, H-2), 3.68 (dd, 2H, 2J = 12.0, 3J = 7.2, H-5), 3.14 (dd, 
2H, 2J = 12.0, 3J = 3.4, H-5), 2.66-2.62 (m, 4H, H-2'), 1.87-1.71 (m, 5H, H-1', NH), 1.43, 1.29 
(2s, 6H, C(CH3)2), 1.41 (s, 18H, CMe3). 13C NMR (DMSO-d6): δ 153.4 (s, CO), 111.2 (s, 
C(CH3)2), 79.2 (d, C-3), 78.3 (s, CMe3), 76.8 (d, C-4), 56.9 (d, C-2), 49.9 (t, C-5), 38.2 (t, C-2'), 
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32.4 (t, C-1'), 27.6 (q, C(CH3)3), 25.9, 24.6 (2q, C(CH3)2). CI-MS: m/z 556 (100, M + H+). CI-
HRMS: m/z 556.3593 (calcd for C28H49N3O8+H: 556.3598). 
(2S, 3R, 4S)-2-Aminoethylpyrrolidine-3,4-diol (13). Deprotection of 11 (94.3 mg, 0.33 mmol) 
according to procedure D gave 13 (47 mg, 98%) as viscous oil. [α] 589
25 = +16 (c = 1.1, MeOH). 1H 
NMR (MeOD): δ 4.20 (m, 1H, H-4), 3.92 (t, 1H, 3J = 4.3, H-3), 3.00–2.92 (m, 2H, H-2, H-5), 
2.84-2.77 (m, 3H, H-5b, H-2’, H-2’), 1.84 (dq, 1H, 2J = 14.0, 3J = 7.1, H-1’), 1.71 (dq, 1H, 3J = 
7.0, H-1’). 13C NMR (MeOD): δ 73.9, 73.4 (2d, C-4, C-3), 60.6 (d, C-2), 51.5 (d, C-5), 39.8 (d, 
C-2’), 32.2 (d, C-1’). CI-MS: m/z 147 (100, [M+H]+). CI-HRMS: m/z 147.1134 (calcd for 
C6H14N2O2+H: 147.1135). 
N,N-Bis-[[(2S, 3R, 4S)-3,4-dihydroxy-pyrrolidinyl]ethyl]amine (5). Deprotection of 12 (100 
mg, 0.18 mmol) according to procedure D gave triamine 5 (49.5 mg, 100%) as viscous oil. 
[α] 589
25 = +8 (c = 0.5, MeOH). IR (KBr): v~  3295, 1690, 1460, 1410, 1095, 805 cm-1. 1H NMR 
(MeOD): δ 4.20 (m, 2H, H-4), 3.92 (dd, 2H, 3J = 4.3, 3J = 4.2, H-3), 3.00–2.92 (m, 4H, H-2, H-
5), 2.84-2.77 (m, 6H, H-5, H-2'), 1.84 (dq, 2H, 2J = 14.0, 3J = 7.1, H-1'), 1.71 (dq, 2H, 2J = 14.0, 
3J = 7.0, H-1'). 13C NMR (MeOD): δ 73.9 (d, C-3), 73.4 (d, C-4), 60.6 (d, C-2), 51.5 (t, C-5), 
39.8 (t, C-2'), 32.2 (t, C-1'). CI-MS: m/z 276 (80, M + H+). CI-HRMS: m/z 276.1922 (calcd for 
C28H49N3O8+H: 276.1923). 
Ethyl N-(tert-butoxycarbonyl)-2,3,6-trideoxy-3,6-imino-4,5-O-isopropylidene-D-arabino-2-
hexanoate (15). To a solution of ethyl 2,3,6-trideoxy-3,6-imino-4,5-O-isopropylidene-D-
arabino-2-hexanoate (14)24 (2.87 g, 12.5 mmol) in dry pyridine (35 mL) was added a solution of 
(Boc)2O (3.06 g, 13.8 mmol) in pyridine (20 mL). The reaction was left at r.t. for 2 h and then 
evaporated. The crude product was dissolved in AcOEt (100 mL) and washed twice with brine. 
The organic layer was dried (Na2SO4), filtered and concentrated. Column chromatography of the 
residue (ether/petroleum ether, 1:5 to 1:2), gave 15 (3.78 g, 92%) as an oil. [α] 589
25 = −68 (c = 1.2, 
CH2Cl2). IR (KBr): v~  2980, 2940, 1720, 1700, 1380, 1090 cm-1. 1H NMR (DMSO-d6, 90 ºC): δ 
4.76 (m, 1H, H-4), 4.73 (m, 1H, H-5), 4.13 (m, 1H, H-3), 4.08 (q, 2H, 2J = 7.1, CH2CH3), 3.60 
(dd, 1H, 3J = 6.5, 2J = 12.7, H-6), 3.26 (dd, 1H, 3J = 2.4, H-6’), 2.85 (dd, 1H, 3J = 4.7, 2J = 16.0, 
H-2), 2.50 (dd, 1H, 2J = 9.6, H-2’), 1.40 (s, 9H, C(CH3)3), 1.41,1.27 (2s, 6H, C(CH3)2), 1.19 (t, 
3H, CH2CH3). 13C NMR (DMSO-d6 90ºC): δ 170.0 (s, CO), 153.3 (s, CO of Boc), 111.1 (s, 
C(CH3)2), 78.9 (d, C-4), 78.7 (s, CMe3), 76.9 (d, C-5), 59.0 (t, CH2CH3), 56.0 (d, C-3), 50.0 (t, 
C-6), 33.8 (t, C-2), 27.6 (q, C(CH3)3), 25.4, 24.5 (2q, C(CH3)2), 13.4 (q, CH2CH3). CI-MS: m/z 
330 (60, [M+H]+). Anal. calcd for C16H27NO6 (329.39): C, 58.34; H, 8.26; N, 4.25. Found: C, 
58.49; H, 8.16; N, 4.32. 
N-(tert-Butoxycarbonyl)-2,3,6-trideoxy-3,6-imino-4,5-O-isopropyliden-D-arabinohexose 
(ent-8). To a solution of ethyl N-(tert-butoxycarbonyl)-2,3,6-trideoxy-3,6-imino-4,5-O-iso-
propyliden-D-arabino-2-hexanoate (15) (0.76 g, 2.32 mmol) in dry dichloromethane (10 mL), 
was added dropwise a solution of DIBAL-H in dichloromethane (1 M, 4.6 mL, 4.6 mmol) at –
78 ºC under Ar. After 2 h at –78ºC MeOH (4 mL) was slowly added, and the reaction mixture 
was left to warm up to r.t. Then the mixture was cooled to 0 ºC, HCl (1M, 10 mL) was added, 
and the mixture was extracted with dichloromethane (4x50 mL). The organic layer was washed 
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with saturated aqueous NaHCO3, dried (Na2SO4), filtered and evaporated. Column 
chromatography of the residue (ether/petroleum ether 1:4 to 1:2) gave ent-8 (0.48 g, 72%) as 
viscous oil. [α] 589
25  = 80 (c = 0.68, CH2Cl2). IR (KBr): v~  2935, 1725, 1400, 1090 cm-1. 1H NMR 
(DMSO-d6, 90 ºC): δ 9.69 (t, 1H, 
3J = 1.7, CHO), 4.79–4.71 (m, 2H, H-4, H-5), 4.21 (c, 1H, 3J = 
6.6, H-3), 3.60 (dd, 1H, 3J = 6.4, 2J = 12.3, H-6), 3.29 (dd, 1H, 3J= 2.3, H-6’), 2.74 (dd, 2H, H-2, 
H-2’), 1.40 (s, 9H, C(CH3)3), 1.41, 1.27 (2s, 6H, C(CH3)2). 13C NMR (DMSO-d6, 90 ºC): δ 200.0 
(s, CHO), 153.4 (s, CO), 111.1 (s, C(CH3)2), 79.0, 76.8 (2d, C-4, C-5), 78.9 (s, CMe3), 55.2 (d, 
C-3), 50.3 (t, C-6), 42.9 (t, C-2), 27.6 (q, C(CH3)3), 25.6 and 24.5 (2q, C(CH3)2). FAB-MS: m/z 
286 (20, [M+H]+). Anal. calcd for C14H23NO5 (285.34): C, 58.93; H, 8.12; N, 4.91. Found: C, 
58.69; H, 8.39; N, 5.16. 
N-(tert-Butoxycarbonyl)-(2R,3S,4R)-2-[2-(benzylamino)ethyl]-3,4-O-isopropylidenepyrrol-
idine-3,4-diol (ent-9) and N,N-bis[N-(tert-butoxycarbonyl)-[(2R,3S,4R)-3,4-O-isopropyl-
idenoxypyrrolidinyl]ethyl]benzylamine (ent-10). Procedure B was applied to carbaldehyde 
ent-8 (327 mg, 1.15 mmol) to afford ent-9 (155.3 mg, 36%) as an oil and ent-10 (95.5 mg, 13%) 
as a white solid. 
ent-9. [α] 589
25  = −47 (c = 0.7, CH2Cl2). CI-HRMS: m/z 377.2439 (calcd for C21H32N2O4+H: 
377.2446). 
ent-10. [α] 589
25 = −88 (c = 0.54, CH2Cl2). CI-MS: m/z 668 (40, M + NH4+), 646 (60, M + H+). CI-
HRMS: m/z 646.4057 (calcd for C35H55N3O8+H: 646.4067). NMR and IR spectra were identical 
to those of its enantiomer 10. 
N-(tert-Butoxycarbonyl)-(2R,3S,4R)-2-aminoethyl-3,4-O-isopropylidene-pyrrolidine-3,4-diol 
(ent-11). A solution of ent-9 (146.3 mg, 0.39 mmol) in abs. EtOH (8 mL) was hydrogenated with 
catalyst Pd/C (10%) (62 mg) at 1 atm for 2 h. The mixture was filtered through Celite and the 
filtrate was evaporated to give ent-11 (111 mg, 100%) as syrup. [α] 589
25 = −55 (c = 0.8, CH2Cl2). 
CIMS: m/z 287 [50%, (M+H)+·]. CI-NSHR: m/z 287.1963 (cald for C14H26N2O4+H: 287.1971). 
This product showed NMR and IR spectra identical to those of its enantiomer 11. 
N,N-Bis[N-(tert-butoxycarbonyl)-[(2R,3S,4R)-3,4-O-isopropylidenoxy-pyrrolidinyl]ethyl] 
amine (ent-12). A solution of ent-10 (90 mg, 0.14 mmol) in THF-MeOH (1.5 mL / 1.5 mL) was 
hydrogenated for 1.5 h under 1 atm with Pd/C (10% on charcoal, 22 mg). The mixture was 
filtered through a pad of Celite and concentrated in vacuo to afford ent-11 (78 mg, 100%) as 
white solid. [α] 589
25 = −62 (c = 0.45, CH2Cl2). CI-MS: m/z 556 (100, M + H+). CI-HRMS: m/z 
556.3589 (calcd for C28H49N3O8+H: 556.3598). NMR and IR spectra were identical to those of 
its enantiomer 12.  
(2R,3S,4R)-2-Aminoethylpyrrolidine-3,4-diol (ent-13). Deprotection of ent-11 (102 mg, 
0.36 mmol) according to procedure D gave ent-13 (52 mg, 91%) as thick oil. [α] 589
25  = −12 (c = 
0.1, MeOH). CI-HRMS m/z 147.1136 (calcd for C6H14N2O2+H: 147.1134). This product showed 
NMR spectra identical to those of its enantiomer 13. 
N,N-bis-[[(2R,3S,4R)-3,4-Dihydroxypyrrolidinyl]ethyl]amine (ent-5). Deprotection of ent-12 
(77 mg, 0.14 mmol) according to procedure D gave ent-5 (37 mg, 97%) as oil. [α] 589
25  = −10 (c = 
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0.78, MeOH). CI-MS: m/z 276 (80, M + H+). CI-HRMS m/z 276.1919 (calcd for C28H49N3O8+H: 
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